Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLCAR.CD30.CCR4 in Relapsed/Refractory CD30+ Hodgkin's Lymphoma
NCT06090864Phase 2Recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Apr 2024
- Primary completion
- Aug 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ATLCAR.CD30.CCR4 cells in Hodgkin lymphoma (HL), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoints: Adverse Events at 6 weeks, Cytokine Release Syndrome at 6 weeks and 2 more. Started Apr 2024; status: recruiting.
02
Drugs
ATLCAR.CD30.CCR4 cells
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT06090864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06090864.